SCHEMBL3479669

SCHEMBL3479669

CN1CCN(c2ccccc2Cl)c2ccc(-c3cncnc3)cc2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 3/20 0.46
KMT2A Q03164 1/20 0.46
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
SLC6A3 Q01959 2/20 0.40
DRD2 P14416 2/20 0.40
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 2/20 0.39
HSD17B10 Q99714 2/20 0.39
HRH4 Q9H3N8 3/20 0.37
SCN9A Q15858 1/20 0.37
PAK1 Q13153 2/20 0.36
PKN1 Q16512 1/20 0.36
DRD3 P35462 1/20 0.35
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3221155 0.89 CYP11B2 (0.46) KMT2ADRD2CYP1A2CYP3A4CYP2D6
SCHEMBL3223146 0.87 WDR5 (0.49) WDR5DRD2CYP1A2HRH4SCN9A
SCHEMBL3229414 0.86 SLC6A2 (0.42) WDR5KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL3226224 0.84 SCN9A (0.45) WDR5KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL3232006 0.83 WDR5 (0.43) WDR5KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL3479501 0.82 SLC6A2 (0.45) WDR5KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL3480219 0.82 HRH4 (0.43) WDR5DRD2CYP1A2CYP3A4CYP2D6
SCHEMBL3225679 0.82 SLC6A2 (0.43) WDR5SLC6A2SLC6A4SLC6A3HSD17B10
SCHEMBL3479437 0.82 SCN9A (0.43) WDR5KMT2ASLC6A2SLC6A4SLC6A3
SCHEMBL3233722 0.81 SCN9A (0.42) DRD2CYP1A2HRH4SCN9APAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D WDR5 1520/4885KMT2A 1229/4885SLC6A2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.